157 related articles for article (PubMed ID: 20435196)
1. Clinical predictors of atrial fibrillation recurrence in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Disertori M; Lombardi F; Barlera S; Latini R; Maggioni AP; Zeni P; Di Pasquale G; Cosmi F; Franzosi MG;
Am Heart J; 2010 May; 159(5):857-63. PubMed ID: 20435196
[TBL] [Abstract][Full Text] [Related]
2. Clinical characteristics of patients with asymptomatic recurrences of atrial fibrillation in the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico-Atrial Fibrillation (GISSI-AF) trial.
Disertori M; Lombardi F; Barlera S; Maggioni AP; Favero C; Franzosi MG; Lucci D; Staszewsky L; Fabbri G; Quintarelli S; Bianconi L; Latini R
Am Heart J; 2011 Aug; 162(2):382-9. PubMed ID: 21835301
[TBL] [Abstract][Full Text] [Related]
3. Valsartan for prevention of recurrent atrial fibrillation.
; Disertori M; Latini R; Barlera S; Franzosi MG; Staszewsky L; Maggioni AP; Lucci D; Di Pasquale G; Tognoni G
N Engl J Med; 2009 Apr; 360(16):1606-17. PubMed ID: 19369667
[TBL] [Abstract][Full Text] [Related]
4. Comparative evaluation of effect of valsartan/amlodipine and atenolol/amlodipine combinations on atrial fibrillation recurrence in hypertensive patients with type 2 diabetes mellitus.
Fogari R; Zoppi A; Mugellini A; Corradi L; Lazzari P; Preti P; Derosa G
J Cardiovasc Pharmacol; 2008 Mar; 51(3):217-22. PubMed ID: 18356684
[TBL] [Abstract][Full Text] [Related]
5. Rationale and design of the GISSI-Atrial Fibrillation Trial: a randomized, prospective, multicentre study on the use of valsartan, an angiotensin II AT1-receptor blocker, in the prevention of atrial fibrillation recurrence.
Disertori M; Latini R; Maggioni AP; Delise P; Di Pasquale G; Franzosi MG; Staszewsky L; Tognoni G;
J Cardiovasc Med (Hagerstown); 2006 Jan; 7(1):29-38. PubMed ID: 16645357
[TBL] [Abstract][Full Text] [Related]
6. Effect of valsartan and ramipril on atrial fibrillation recurrence and P-wave dispersion in hypertensive patients with recurrent symptomatic lone atrial fibrillation.
Fogari R; Derosa G; Ferrari I; Corradi L; Zoppi A; Lazzari P; Santoro T; Preti P; Mugellini A
Am J Hypertens; 2008 Sep; 21(9):1034-9. PubMed ID: 18566593
[TBL] [Abstract][Full Text] [Related]
7. Circulating cardiovascular biomarkers in recurrent atrial fibrillation: data from the GISSI-atrial fibrillation trial.
Latini R; Masson S; Pirelli S; Barlera S; Pulitano G; Carbonieri E; Gulizia M; Vago T; Favero C; Zdunek D; Struck J; Staszewsky L; Maggioni AP; Franzosi MG; Disertori M;
J Intern Med; 2011 Feb; 269(2):160-71. PubMed ID: 20964739
[TBL] [Abstract][Full Text] [Related]
8. Management of persistent atrial fibrillation following balloon mitral valvotomy: safety and efficacy of low-dose amiodarone.
Kapoor A; Kumar S; Singh RK; Pandey CM; Sinha N
J Heart Valve Dis; 2002 Nov; 11(6):802-9. PubMed ID: 12479281
[TBL] [Abstract][Full Text] [Related]
9. A comparison between oral antiarrhythmic drugs in the prevention of atrial fibrillation after cardiac surgery: the pilot study of prevention of postoperative atrial fibrillation (SPPAF), a randomized, placebo-controlled trial.
Auer J; Weber T; Berent R; Puschmann R; Hartl P; Ng CK; Schwarz C; Lehner E; Strasser U; Lassnig E; Lamm G; Eber B;
Am Heart J; 2004 Apr; 147(4):636-43. PubMed ID: 15077078
[TBL] [Abstract][Full Text] [Related]
10. High-sensitivity C-reactive protein is predictive of successful cardioversion for atrial fibrillation and maintenance of sinus rhythm after conversion.
Watanabe E; Arakawa T; Uchiyama T; Kodama I; Hishida H
Int J Cardiol; 2006 Apr; 108(3):346-53. PubMed ID: 15964643
[TBL] [Abstract][Full Text] [Related]
11. N-3 polyunsaturated fatty acids administration does not reduce the recurrence rates of atrial fibrillation and inflammation after electrical cardioversion: a prospective randomized study.
Ozaydın M; Erdoğan D; Tayyar S; Uysal BA; Doğan A; Içli A; Ozkan E; Varol E; Türker Y; Arslan A
Anadolu Kardiyol Derg; 2011 Jun; 11(4):305-9. PubMed ID: 21543294
[TBL] [Abstract][Full Text] [Related]
12. Statins and amiodarone improve freedom from recurrence of atrial fibrillation after successful cardioversion.
Naji F; Suran D; Kanic V; Vokac D; Sabovic M
Med Sci Monit; 2009 Sep; 15(9):CR494-8. PubMed ID: 19721402
[TBL] [Abstract][Full Text] [Related]
13. Incidence of atrial fibrillation in relation to changing heart rate over time in hypertensive patients: the LIFE study.
Okin PM; Wachtell K; Kjeldsen SE; Julius S; Lindholm LH; Dahlöf B; Hille DA; Nieminen MS; Edelman JM; Devereux RB
Circ Arrhythm Electrophysiol; 2008 Dec; 1(5):337-43. PubMed ID: 19808428
[TBL] [Abstract][Full Text] [Related]
14. Electrical cardioversion for persistent atrial fibrillation or atrial flutter in clinical practice: predictors of long-term outcome.
Boriani G; Diemberger I; Biffi M; Domenichini G; Martignani C; Valzania C; Branzi A
Int J Clin Pract; 2007 May; 61(5):748-56. PubMed ID: 17493088
[TBL] [Abstract][Full Text] [Related]
15. Oral amiodarone increases the efficacy of direct-current cardioversion in restoration of sinus rhythm in patients with chronic atrial fibrillation.
Capucci A; Villani GQ; Aschieri D; Rosi A; Piepoli MF
Eur Heart J; 2000 Jan; 21(1):66-73. PubMed ID: 10610746
[TBL] [Abstract][Full Text] [Related]
16. Relation of C-reactive protein to long-term risk of recurrence of atrial fibrillation after electrical cardioversion.
Loricchio ML; Cianfrocca C; Pasceri V; Bianconi L; Auriti A; Calo L; Lamberti F; Castro A; Pandozi C; Palamara A; Santini M
Am J Cardiol; 2007 May; 99(10):1421-4. PubMed ID: 17493472
[TBL] [Abstract][Full Text] [Related]
17. Amiodarone prophylaxis for atrial fibrillation of high-risk patients after coronary bypass grafting: a prospective, double-blinded, placebo-controlled, randomized study.
Budeus M; Hennersdorf M; Perings S; Röhlen S; Schnitzler S; Felix O; Reimert K; Feindt P; Gams E; Lehmann N; Wieneke H; Sack S; Erbel R; Perings C
Eur Heart J; 2006 Jul; 27(13):1584-91. PubMed ID: 16760210
[TBL] [Abstract][Full Text] [Related]
18. Prevalence, pathophysiology, and clinical significance of post-heart transplant atrial fibrillation and atrial flutter.
Ahmari SA; Bunch TJ; Chandra A; Chandra V; Ujino K; Daly RC; Kushwaha SS; Edwards BS; Maalouf YF; Seward JB; McGregor CG; Chandrasekaran K
J Heart Lung Transplant; 2006 Jan; 25(1):53-60. PubMed ID: 16399531
[TBL] [Abstract][Full Text] [Related]
19. Antiarrhythmic drug prescription in patients after myocardial infarction in the last decade. Experience of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico (GISSI).
Avanzini F; Latini R; Maggioni A; Colombo F; Santoro E; Franzosi MG; Tognoni G
Arch Intern Med; 1995 May; 155(10):1041-5. PubMed ID: 7748046
[TBL] [Abstract][Full Text] [Related]
20. Effect of atorvastatin on the recurrence rates of atrial fibrillation after electrical cardioversion.
Ozaydin M; Varol E; Aslan SM; Kucuktepe Z; Dogan A; Ozturk M; Altinbas A
Am J Cardiol; 2006 May; 97(10):1490-3. PubMed ID: 16679090
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
